Pall hiring 300 to staff South Carolina plant

Pall will hire 300 people to staff its single-use bioprocessing manufacturing facility in Duncan, South Carolina.

Millie Nelson, Editor

November 12, 2021

2 Min Read
Pall hiring 300 to staff South Carolina plant
Image: Stock Photo Secrets

Pall will hire 300 people to staff its single-use bioprocessing manufacturing facility in Duncan, South Carolina.

Cytiva and Pall announced a $1.5 billion investment in July (in addition to Cytiva’s $500 million growth strategy that was announced in September 2020 and January) to expand manufacturing capacity for life sciences products at thirteen Danaher Corporation sites to meet customer demand.

Part of this investment includes the construction of facilities in the US and the UK over the next two years.


Image: Stock Photo Secrets

Now Pall is recruiting 300 people for its recently opened 220,000 square-foot Duncan plant, which will mostly manufacture single-use bioprocessing equipment.

The firm has already hired 100 employees over the summer, but Joseph Repp, president, Pall Life Sciences told BioProcess Insider “we have 300 more positions to fill at the site.”

“We are partnering closely with local government and state agencies, the Duncan community, chamber of commerce and business leaders to raise awareness of our business and new operations in Duncan,” said Repp.

“We are also advertising to recruit for 300 open positions in Duncan, holding career fairs and believe our comprehensive benefits package and opportunities for career advancement will attract the talent we need to grow our business here.”

According to Pall, the local talent pool in South Carolina is what attracted it to invest in the area.

“The South Carolina area is very attractive to us and will provide us with access to some of the best talent in the country for both professional positions and manufacturing roles with opportunities for advancement,” Repp told us.

Single-use demand

Single-use equipment has become a standard part of the biomanufacturing landscape. A report in September 2020  estimated that around 85% of pre-commercial product manufacturing involves very substantial single-use systems-based manufacturing, while disposable equipment is being used in a commercial setting.

Such demand, meanwhile, has shot up further due to coronavirus pandemic with some reports of lead times up to 12 months on some products in the industry.

Pall is not the only firm expediting single-use supply. Other firms include MilliporeSigma accelerated its plans in March to add a single-use assembly production unit at its site in Molsheim, France.

Meanwhile, biopharma tubing firm Venair also broke ground on a $6 million Spanish facility to double the company’s single-use equipment capacity in May and in September, Thermo Fisher also doubled its single-use capacity through construction of its $100 million plant in Wilson County, Tennessee.

About the Author(s)

Millie Nelson

Editor, BioProcess Insider

Journalist covering global biopharmaceutical manufacturing and processing news and host of the Voices of Biotech podcast.

I am currently living and working in London but I grew up in Lincolnshire (UK) and studied in Newcastle (UK).

Got a story? Feel free to email me at [email protected]

You May Also Like